Ami Vyas1, Tyler Mantaian2, Shweta Kamat2, Sobha Kurian3, Stephen Kogut2. 1. University of Rhode Island, College of Pharmacy, Department of Pharmacy Practice, Kingston, RI, United States of America. Electronic address: AVyas@uri.edu. 2. University of Rhode Island, College of Pharmacy, Department of Pharmacy Practice, Kingston, RI, United States of America. 3. West Virginia University, School of Medicine, Morgantown, WV, United States of America.
Abstract
PURPOSE: We examined guideline-concordant initial systemic treatment among women with metastatic breast cancer, its predictors, and if guideline-concordant treatment was associated with mortality, healthcare utilization and Medicare expenditures. METHODS: This retrospective observational cohort study was conducted using the Surveillance, Epidemiology, End Results-Medicare linked database. Women aged 66-90 years diagnosed with metastatic breast cancer during 2010-2013 (N = 1282) were included. The National Comprehensive Cancer Network treatment guidelines were used to determine the guideline-concordant initial systemic treatment following cancer diagnosis. A logistic regression analysis was conducted to examine significant predictors of guideline-concordant treatment. Generalized linear regressions were used to examine the association between guideline-concordant treatment and healthcare utilization and average monthly Medicare expenditures. RESULTS: About 74% of the study cohort received guideline-concordant initial systemic treatment. Women who received guideline-concordant treatment were significantly more likely to be comparatively younger (p < 0.05), were married/partnered (p = 0.0038), had HER2 positive tumors, and had good performance status. Adjusted hazards ratios for all-cause (2.364, p < 0.0001) and breast-cancer specific mortality (2.179, p < 0.0001) were higher for women who did not receive guideline-concordant treatment. Rates of healthcare utilization were also higher for women not receiving guideline-concordant treatment. Average monthly Medicare expenditures were 100.4% higher (95% confidence interval: $77.3%-126.5%) for women who did not receive guideline-concordant treatment compared to those who received guideline-concordant treatment (p < 0.0001). CONCLUSION: One fourth of the study cohort did not receive guideline-concordant initial systemic treatment. Guideline-concordant initial treatment was associated with reduced mortality, and lower healthcare utilization and Medicare expenditures in women with metastatic breast cancer.
PURPOSE: We examined guideline-concordant initial systemic treatment among women with metastatic breast cancer, its predictors, and if guideline-concordant treatment was associated with mortality, healthcare utilization and Medicare expenditures. METHODS: This retrospective observational cohort study was conducted using the Surveillance, Epidemiology, End Results-Medicare linked database. Women aged 66-90 years diagnosed with metastatic breast cancer during 2010-2013 (N = 1282) were included. The National Comprehensive Cancer Network treatment guidelines were used to determine the guideline-concordant initial systemic treatment following cancer diagnosis. A logistic regression analysis was conducted to examine significant predictors of guideline-concordant treatment. Generalized linear regressions were used to examine the association between guideline-concordant treatment and healthcare utilization and average monthly Medicare expenditures. RESULTS: About 74% of the study cohort received guideline-concordant initial systemic treatment. Women who received guideline-concordant treatment were significantly more likely to be comparatively younger (p < 0.05), were married/partnered (p = 0.0038), had HER2 positive tumors, and had good performance status. Adjusted hazards ratios for all-cause (2.364, p < 0.0001) and breast-cancer specific mortality (2.179, p < 0.0001) were higher for women who did not receive guideline-concordant treatment. Rates of healthcare utilization were also higher for women not receiving guideline-concordant treatment. Average monthly Medicare expenditures were 100.4% higher (95% confidence interval: $77.3%-126.5%) for women who did not receive guideline-concordant treatment compared to those who received guideline-concordant treatment (p < 0.0001). CONCLUSION: One fourth of the study cohort did not receive guideline-concordant initial systemic treatment. Guideline-concordant initial treatment was associated with reduced mortality, and lower healthcare utilization and Medicare expenditures in women with metastatic breast cancer.
Authors: Cynthia Osborne; Glenn V Ostir; Xianglin Du; M Kristen Peek; James S Goodwin Journal: Breast Cancer Res Treat Date: 2005-09 Impact factor: 4.872
Authors: Dorien J A Lobbezoo; Roel J W van Kampen; Adri C Voogd; M Wouter Dercksen; Franchette van den Berkmortel; Tineke J Smilde; Agnes J van de Wouw; Frank P J Peters; Johanna M G H van Riel; Natascha A J B Peters; Maaike de Boer; George F Borm; Vivianne C G Tjan-Heijnen Journal: Breast Cancer Res Treat Date: 2013-10-09 Impact factor: 4.872
Authors: Philip D Poorvu; Ines Vaz-Luis; Rachel A Freedman; Nancy U Lin; William T Barry; Eric P Winer; Michael J Hassett Journal: Breast Cancer Res Treat Date: 2018-01-13 Impact factor: 4.872
Authors: Richard L Theriault; Robert W Carlson; Craig Allred; Benjamin O Anderson; Harold J Burstein; Stephen B Edge; William B Farrar; Andres Forero; Sharon Hermes Giordano; Lori J Goldstein; William J Gradishar; Daniel F Hayes; Clifford A Hudis; Steven J Isakoff; Britt-Marie E Ljung; David A Mankoff; P Kelly Marcom; Ingrid A Mayer; Beryl McCormick; Lori J Pierce; Elizabeth C Reed; Lee S Schwartzberg; Mary Lou Smith; Hatem Soliman; George Somlo; John H Ward; Antonio C Wolff; Richard Zellars; Dorothy A Shead; Rashmi Kumar Journal: J Natl Compr Canc Netw Date: 2013-07 Impact factor: 11.908
Authors: Gabrielle B Rocque; Courtney P Williams; Bradford E Jackson; Stacey A Ingram; Karian I Halilova; Maria Pisu; Kelly M Kenzik; Andres Azuero; Andres Forero; Smita Bhatia Journal: J Natl Compr Canc Netw Date: 2018-09 Impact factor: 11.908
Authors: Tomi F Akinyemiju; Amr S Soliman; Norman J Johnson; Sean F Altekruse; Kathy Welch; Mousumi Banerjee; Kendra Schwartz; Sofia Merajver Journal: J Cancer Epidemiol Date: 2013-02-20